Shares of CSL CSL.AX rise as much as 3.5% to A$147.90, their highest level since February 24
Co's vaccine business, CSL Seqirus, wins contract to support influenza pandemic preparedness plans of the Canadian government, per Australia-Canada joint statement
CSL Seqirus' advanced cell-based vaccine manufacturing facility in Australia to supply Canada with 15 million vaccines in the event of a pandemic
Stock down 15% this year, including the day's move